Skip to content

Esperion Therapeutics, Inc.: 10-K filed 2014-03-13

What Esperion Therapeutics, Inc. reported in its annual report filed 2014-03-13 (fiscal FY 2013): 25 published measures, 123 facts as tagged in accession 0001047469-14-002320.

This filing

Form
10-K (annual report)
Filed
2014-03-13
Fiscal period
fiscal FY 2013
Accession
0001047469-14-002320 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Esperion Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-3178,293,860USD
At 2012-12-317,312,441USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-314,202,491USD
At 2012-12-3124,702,144USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-3174,091,369USD
At 2012-12-31-41,364,703USD
At 2011-12-31-30,031,806USD
At 2010-12-31-19,313,202USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-3156,537,361USD
At 2012-12-316,511,521USD
At 2011-12-311,571,084USD
At 2010-12-313,414,896USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-9,689,446USD92
2013-01-01 to 2013-12-31-26,088,133USD365
2008-01-22 to 2013-12-31-68,063,158USD2171
2013-07-01 to 2013-09-30-5,238,434USD92
2013-04-01 to 2013-06-30-6,921,076USD91
2013-01-01 to 2013-03-31-4,239,177USD90
2012-10-01 to 2012-12-31-2,775,356USD92
2012-01-01 to 2012-12-31-11,741,736USD366
2012-07-01 to 2012-09-30-3,351,274USD92
2012-04-01 to 2012-06-30-3,166,154USD91
2012-01-01 to 2012-03-31-2,448,952USD91
2011-01-01 to 2011-12-31-10,817,341USD365
2008-01-22 to 2010-12-31-19,415,948USD1075

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-12-3131,373USD365
2008-01-22 to 2013-12-31298,932USD2171
2012-01-01 to 2012-12-316,783USD366
2011-01-01 to 2011-12-3133,635USD365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-01-01 to 2013-12-310USD365
2012-01-01 to 2012-12-310USD366
2011-01-01 to 2011-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-12-3180,808USD
At 2012-12-31120,210USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-12-311,226,988USD365
2008-01-22 to 2013-12-311,484,096USD2171
2012-01-01 to 2012-12-3179,861USD366
2011-01-01 to 2011-12-3178,451USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-9,736,016USD92
2013-01-01 to 2013-12-31-22,758,698USD365
2008-01-22 to 2013-12-31-61,463,388USD2171
2013-07-01 to 2013-09-30-5,406,823USD92
2013-04-01 to 2013-06-30-4,271,847USD91
2013-01-01 to 2013-03-31-3,344,012USD90
2012-10-01 to 2012-12-31-2,160,047USD92
2012-01-01 to 2012-12-31-10,203,760USD366
2012-07-01 to 2012-09-30-2,990,249USD92
2012-04-01 to 2012-06-30-2,863,881USD91
2012-01-01 to 2012-03-31-2,189,583USD91
2011-01-01 to 2011-12-31-10,164,371USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-3160,619,649USD
At 2012-12-317,138,406USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-12-31936,580USD365
2008-01-22 to 2013-12-314,320,696USD2171
2013-04-01 to 2013-06-30108,357USD91
2013-01-01 to 2013-03-31828,223USD90
2012-10-01 to 2012-12-31561,675USD92
2012-01-01 to 2012-12-311,486,696USD366
2012-07-01 to 2012-09-30361,426USD92
2012-04-01 to 2012-06-30303,167USD91
2012-01-01 to 2012-03-31260,428USD91
2011-01-01 to 2011-12-31577,157USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-314,202,491USD
At 2012-12-3117,173,299USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-312,231,890USD
At 2012-12-31476,277USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-10-01 to 2013-12-319,736,016USD92
2013-01-01 to 2013-12-3122,758,698USD365
2008-01-22 to 2013-12-3161,707,867USD2171
2013-07-01 to 2013-09-305,406,823USD92
2013-04-01 to 2013-06-304,271,847USD91
2013-01-01 to 2013-03-313,344,012USD90
2012-10-01 to 2012-12-312,160,047USD92
2012-01-01 to 2012-12-3110,203,760USD366
2012-07-01 to 2012-09-302,990,249USD92
2012-04-01 to 2012-06-302,863,881USD91
2012-01-01 to 2012-03-312,189,583USD91
2011-01-01 to 2011-12-3110,164,371USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-3115,340,710shares
At 2012-12-31346,478shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-31142,142,204USD
At 2012-12-31609,976USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2013-12-31-3,034USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-12-31768,607USD
At 2012-12-311,286,046USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-12-31687,799USD
At 2012-12-311,165,836USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-26,091,167USD365
2008-01-22 to 2013-12-31-68,066,192USD2171
2012-01-01 to 2012-12-31-11,741,736USD366
2011-01-01 to 2011-12-31-10,817,341USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-312,397,499USD92
2013-01-01 to 2013-12-316,744,493USD365
2008-01-22 to 2013-12-3118,194,189USD2171
2013-07-01 to 2013-09-301,924,150USD92
2013-04-01 to 2013-06-301,171,425USD91
2013-01-01 to 2013-03-311,251,419USD90
2012-10-01 to 2012-12-31505,765USD92
2012-01-01 to 2012-12-312,205,632USD366
2012-07-01 to 2012-09-30533,837USD92
2012-04-01 to 2012-06-30533,658USD91
2012-01-01 to 2012-03-31632,372USD91
2011-01-01 to 2011-12-312,356,669USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-12-3170,551USD365
2008-01-22 to 2013-12-311,447,722USD2171
2012-01-01 to 2012-12-31139,433USD366
2011-01-01 to 2011-12-31178,471USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-10-01 to 2013-12-3146,570USD92
2013-01-01 to 2013-12-31194,010USD365
2008-01-22 to 2013-12-31275,424USD2171
2013-07-01 to 2013-09-30168,389USD92
2013-04-01 to 2013-06-304,035USD91
2013-01-01 to 2013-03-31-24,984USD90
2012-10-01 to 2012-12-31-86,001USD92
2012-01-01 to 2012-12-31-83,647USD366
2012-07-01 to 2012-09-30401USD92
2012-04-01 to 2012-06-30894USD91
2012-01-01 to 2012-03-311,059USD91
2011-01-01 to 2011-12-31-75,813USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-311,755,613USD365
2008-01-22 to 2013-12-312,231,890USD2171
2012-01-01 to 2012-12-31-214,903USD366
2011-01-01 to 2011-12-31619,238USD365

Inspect the source

Entity
Esperion Therapeutics, Inc. / CIK 0001434868
Captured
2026-09-21T17:19:05.322Z
SEC response SHA-256
c855d6a6c2d879a88675aebb590fdc9935826605a25a04ffeec1282218bce6bf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001434868.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))